TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time from muscle relaxant to muscle closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to TOFR of 0.25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to TOFR of 0.50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Desaturation events
Endpoint domain: Adverse events/effects
Primary endpoint: CGIC response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NBRS‐A response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Closure rate for tympanoplasty type I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean ABG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to failure of the hemofilter
Endpoint domain: Mortality/survival
Primary endpoint: Coronary artery dilation response to nitroglycerin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breast milk as the only milk source
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Daily family meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Reduced obesity-promoting feeding practices
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: esophagitis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of grade ≥3 esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: esophageal expansion imaging biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: newborn weight loss >7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KCCQ functional improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KCCQ overall improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BDI improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: actuarial biochemical control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aPTT effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dose of physical activity delivered per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible children participating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Levels of inflammatory markers (CRP, TNFalpha, vWF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in obsession-related distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma volume (PV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal discrepancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall WHOQOL-BREF scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fibroid recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic effect for treatment of insomnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corrected birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: placental growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC membrane DHA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-related activity interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of endothelial function (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in oxidative stress (15-F(2t)-Isoprostane)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total obvious effect rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to use of rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global ratings of analgesic efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: abnormal acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: needle control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Progression of vertebral compression after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New postoperative fractures during follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: MRSA eradication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pump failure death
Endpoint domain: Mortality/survival
Primary endpoint: favorable functional survival at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Composite outcome of death and major disability
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive deficiencies measured by Digit Span Test and N-back Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concordance with guideline treatment recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Visual Acuity (VA) at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative shoulder tip pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesic requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity for CMRI depicting coronary artery disease with relevant stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity for CMRI depicting coronary artery disease with relevant stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of CMRI in predicting relevant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No nasal blockage, sneezing, or rhinorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morning peak-flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ALT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: HCV RNA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: weight change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microleakage scores at the gingival margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in objective measures of SOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Implant survival
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived enhancement difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of identifying low-dose examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Healthgrades in reporting board certification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of primary substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participants' and providers' experiences and expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of progression to CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Consumption of rescue oxycodone
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fatigue throughout the day of surgery
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean metformin plasma concentration-time profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sitagliptin plasma concentration-time profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse experiences reported
Endpoint domain: Adverse events/effects
Primary endpoint: PANSS Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAS
Endpoint domain: Adverse events/effects
Primary endpoint: BAS
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid analgesic requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VAS values (postoperative pain sensation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inhibition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incident microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: single-foot supporting phase rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss at cesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postpartum endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of reproductive health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Lequesne index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (ORR)
Endpoint domain: Mortality/survival
Primary endpoint: Median time to tumor progression
Endpoint domain: Mortality/survival
Primary endpoint: clinically driven target‐vessel revascularization by 8 months
Endpoint domain: Mortality/survival
Primary endpoint: incidence of composite including death, myocardial infarction, and target‐vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: binary 8‐month angiographic restenosis (> or =50% diameter stenosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung Injury Score (LIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of PaO2 to FIO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Multiple Organ Dysfunction Score (MODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality associated with intensive care unit
Endpoint domain: Mortality/survival
Primary endpoint: plasma cyclic AMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Child BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WORC index at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: menstrual disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cumulative number of gadolinium-enhancing MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet aggregation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mature cross-link HHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: advanced glycation end-product NFC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTB total composite z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: task performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fentanyl bolus consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of ischaemic or unspecified stroke or systemic embolus (SSE)
Endpoint domain: Mortality/survival
Primary endpoint: Ventilator-associated pneumonia frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intensive care unit mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Intensive care unit mortality at the end of stay
Endpoint domain: Mortality/survival
Primary endpoint: BMD loss at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD loss at the total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry mouth symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: disease relapse
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to hemodialysis dietary recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy for restricting sodium intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurocognitive z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum creatinine and blood urea nitrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in confidence with following hypertension treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GH levels after sumatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cognitive and executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: general development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average air conduction pure tone thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average air-bone gap (ABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone conduction (BC) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of psychotic and PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful maintenance on monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to meet escape criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased reinfarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achievement scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Non-compliance with HT cessation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Impairment due to gas-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Uterine volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic lymphoceles
Endpoint domain: Adverse events/effects
Primary endpoint: Positive BRPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kinaesiophobia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibody concentration ≥ 0.2 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OPA titre ≥ 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-protein D geometric mean antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Driving ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of DRB1 * 0101.2 and DRB1 * 0302 alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relapse rate during 6 months' follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meningitis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Shunt infection risk
Endpoint domain: Adverse events/effects
Primary endpoint: CGI severity of depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foreign body sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of auxiliary treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0‐12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐ yen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial lipoatrophy severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue depth change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 count increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of confirmed pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: severe neonatal jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: avoidance of exchange transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-controlled analgesia usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction (visual analog scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain during activity (visual analog scores)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Children's dietary diversity scores (CDDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrition knowledge scores of the caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-management scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FEV1% change from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: blood lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: endometrial effects
Endpoint domain: Adverse events/effects
Primary endpoint: peak CBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: live delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central macular thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pre-eclampsia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Health economic value of abatacept compared to adalimumab
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Graft shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in the recipient site
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhibition of maximal aggregation with 20 microM ADP stimuli at 30-day follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of late aggregation with 20 microM ADP stimuli at 30-day follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: High-postclopidogrel platelet reactivity at 30-day follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of radiation pneumonia >= grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: NPS 10 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes